Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study
Abstract
:1. Introduction
2. Methods
2.1. Case Series
2.2. Literature Review
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Armstrong, A.W.; Read, C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA 2020, 323, 1945–1960. [Google Scholar] [CrossRef] [PubMed]
- Yamazaki, F. Psoriasis: Comorbidities. J. Dermatol. 2021, 48, 732–740. [Google Scholar] [CrossRef] [PubMed]
- Pouplard, C.; Brenaut, E.; Horreau, C.; Barnetche, T.; Misery, L.; Richard, M.A.; Aractingi, S.; Aubin, F.; Cribier, B.; Joly, P.; et al. Risk of cancer in psoriasis: A systematic review and meta-analysis of epidemiological studies. J. Eur. Acad. Dermatol. Venereol. 2013, 27 (Suppl. S3), 36–46. [Google Scholar] [CrossRef] [PubMed]
- Lee, J.H.; Kim, H.J.; Han, K.D.; Kim, H.N.; Park, Y.M.; Lee, J.Y.; Park, Y.G.; Lee, Y.B. Cancer risk in 892 089 patients with psoriasis in Korea: A nationwide population-based cohort study. J. Dermatol. 2019, 46, 95–102. [Google Scholar] [CrossRef] [PubMed]
- Dai, H.; Li, W.-Q.; Qureshi, A.A.; Han, J. Personal history of psoriasis and risk of nonmelanoma skin cancer (NMSC) among women in the United States: A population-based cohort study. J. Am. Acad. Dermatol. 2016, 75, 731–735. [Google Scholar] [CrossRef]
- Egeberg, A.; Thyssen, J.P.; Gislason, G.H.; Skov, L. Skin cancer in patients with psoriasis. J. Eur. Acad. Dermatol. Venereol. 2016, 30, 1349–1353. [Google Scholar] [CrossRef] [PubMed]
- Avina-Zubieta, J.A.; Dominique, A.; Simon, T.A. Risk of Cancer in Patients with Psoriasis/Psoriatic Arthritis: A Population-Based Study in the Province of British Columbia [Abstract 1588]. Published 2018. Available online: https://acrabstracts.org/abstract/risk-of-cancer-in-patients-with-psoriasis-psoriatic-arthritis-a-population-based-study-in-the-province-of-british-columbia/ (accessed on 17 January 2020).
- Chiesa Fuxench, Z.C.; Shin, D.B.; Ogdie Beatty, A.; Gelfand, J.M. The risk of cancer in patients with psoriasis: A population-based cohort study in the health improvement network. JAMA Dermatol. 2016, 152, 282–290. [Google Scholar] [CrossRef] [PubMed]
- Wild, C.P.; Scalbert, A.; Herceg, Z. Measuring the exposome: A powerful basis for evaluating environmental exposures and cancer risk. Environ. Mol. Mutagen. 2013, 54, 480–499. [Google Scholar] [CrossRef] [PubMed]
- Özdemir, Ö. RETRACTED: Preventative and Therapeutic Role of Probiotics in Various Allergic and Autoimmune Disorders: An Up-to-Date Literature Review of Essential Experimental and Clinical Data. J. Evid. Based Complement. Altern. Med. 2013, 18, 121–151. [Google Scholar] [CrossRef]
- Vaengebjerg, S.; Skov, L.; Egeberg, A.; Loft, N.D. Prevalence, Incidence, and Risk of Cancer in Patients with Psoriasis and Psoriatic Arthritis: A Systematic Review and Meta-analysis. JAMA Dermatol. 2020, 156, 421–429. [Google Scholar] [CrossRef]
- Rademaker, M.; Rubel, D.M.; Agnew, K.; Andrews, M.; Armour, K.S.; Baker, C.; Foley, P.; Gebauer, K.; Goh, M.S.; Gupta, M.; et al. Psoriasis and cancer. An Australian/New Zealand narrative. Australas. J. Dermatol. 2019, 60, 12–18. [Google Scholar] [CrossRef]
- Loft, N.D.; Vaengebjerg, S.; Skov, L. Cancer risk in patients with psoriasis: Should we be paying more attention? Expert. Rev. Clin. Immunol. 2020, 16, 479–492. [Google Scholar] [CrossRef]
- Lindelöf, B.; Sigurgeirsson, B.; Tegner, E.; Larkö, O.; Johannesson, A.; Berne, B.; Ljunggren, B.; Andersson, T.; Molin, L.; Nylander-Lundqvist, E.; et al. PUVA and cancer risk: The Swedish follow-up study. Br. J. Dermatol. 1999, 141, 108–112. [Google Scholar] [CrossRef] [PubMed]
- Didona, D.; Paolino, G.; Bottoni, U.; Cantisani, C. Non melanoma skin cancer pathogenesis overview. Biomedicines 2018, 6, 6. [Google Scholar] [CrossRef]
- Kamstrup, M.R.; Skov, L.; Zachariae, C.; Thyssen, J.P.; Egeberg, A. Psoriasis and risk of malignant lymphoma: A population-based cohort study. Br. J. Dermatol. 2018, 178, 1435–1436. [Google Scholar] [CrossRef] [PubMed]
- Nast, A.; Smith, C.; Spuls, P.I.; Avila Valle, G.; Bata-Csörgö, Z.; Boonen, H.; De Jong, E.; Garcia-Doval, I.; Gisondi, P.; Kaur-Knudsen, D.; et al. EuroGuiDerm Guideline on the systemic treatment of Psoriasis vulgaris-Part 2: Specific clinical and comorbid situations. J. Eur. Acad. Dermatol. Venereol. 2021, 35, 281–317. [Google Scholar] [CrossRef]
- Florek, A.G.; Wang, C.J.; Armstrong, A.W. Treatment preferences and treatment satisfaction among psoriasis patients: A systematic review. Arch. Dermatol. Res. 2018, 310, 271–319. [Google Scholar] [CrossRef]
- Dave, R.; Alkeswani, A. An Overview of Biologics for Psoriasis. J. Drugs Dermatol. 2021, 20, 1246–1247. [Google Scholar] [CrossRef] [PubMed]
- Ruggiero, A.; Picone, V.; Martora, F.; Fabbrocini, G.; Megna, M. Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence. Clin. Cosmet. Investig. Dermatol. 2022, 15, 1649–1658. [Google Scholar] [CrossRef]
- Kamata, M.; Tada, Y. Efficacy and Safety of Biologics for Psoriasis and Psoriatic Arthritis and Their Impact on Comorbidities: A Literature Review. Int. J. Mol. Sci. 2020, 21, 1690. [Google Scholar] [CrossRef]
- Yiu, Z.Z.N.; Becher, G.; Kirby, B.; Laws, P.; Reynolds, N.J.; Smith, C.H.; Warren, R.B.; Griffiths, C.E.M.; Browne, F.; Evans, I.; et al. Drug Survival Associated with Effectiveness and Safety of Treatment with Guselkumab, Ixekizumab, Secukinumab, Ustekinumab, and Adalimumab in Patients with Psoriasis. JAMA Dermatol. 2022, 158, 1131–1141. [Google Scholar] [CrossRef]
- Gisondi, P.; Altomare, G.; Ayala, F.; Bardazzi, F.; Bianchi, L.; Chiricozzi, A.; Costanzo, A.; Conti, A.; Dapavo, P.; De Simone, C.; et al. Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. J. Eur. Acad. Dermatol. Venereol. 2017, 31, 774–790. [Google Scholar] [CrossRef]
- Dressler, C.; Rosumeck, S.; Werner, R.N.; van der Kraaij, G.; van Lumig, P.; Wakkee, M.; Spuls, P.; Nast, A. Methods report: European S3-Guideline on the systemic treatment of psoriasis vulgaris-Update Apremilast and Secukinumab-EDF in cooperation with EADV and IPC. J. Eur. Acad. Dermatol. Venereol. 2017, 31, 1964–1977. [Google Scholar] [CrossRef]
- Feldman, S.R.; Menter, A.M. Biologics for psoriasis: Is there any unmet need left? Expert. Opin. Biol. Ther. 2022, 22, 1429. [Google Scholar] [CrossRef] [PubMed]
- Chyuan, I.T.; Lai, J.H. New insights into the IL-12 and IL-23: From a molecular basis to clinical application in immune-mediated inflammation and cancers. Biochem. Pharmacol. 2020, 175, 113928. [Google Scholar] [CrossRef]
- Zhao, J.; Chen, X.; Herjan, T.; Li, X. The role of interleukin-17 in tumor development and progression. J. Exp. Med. 2020, 217, e20190297. [Google Scholar] [CrossRef]
- Balkwill, F. Tumour necrosis factor and cancer. Nat. Rev. Cancer 2009, 9, 361–371. [Google Scholar] [CrossRef] [PubMed]
- Quéreux, G.; Renaut, J.J.; Peuvrel, L.; Knol, A.C.; Brocard, A.; Dréno, B. Sudden onset of an aggressive cutaneous lymphoma in a young patient with psoriasis: Role of immunosuppressants. Acta Derm.-Venereol. 2010, 90, 616–620. [Google Scholar] [PubMed]
- Balak, D.; Hajdarbegovic, E. Drug-induced psoriasis: Clinical perspectives. Psoriasis Targets Ther. 2017, 7, 87–94. [Google Scholar] [CrossRef]
- Megna, M.; Potestio, L.; Battista, T.; Camela, E.; Genco, L.; Noto, M.; Fabbrocini, G.; Martora, F. Immune response to COVID-19 mRNA vaccination in patients with psoriasis undergoing treatment with biologics. Clin. Exp. Dermatol. 2022, 47, 2310–2312. [Google Scholar] [CrossRef]
- Bonigen, J.; Raynaud-Donzel, C.; Hureaux, J.; Kramkimel, N.; Blom, A.; Jeudy, G.; Breton, A.L.; Hubiche, T.; Bedane, C.; Legoupil, D.; et al. Anti-PD1-induced psoriasis: A study of 21 patients. J. Eur. Acad. Dermatol. Venereol. 2017, 31, e254–e257. [Google Scholar] [CrossRef] [PubMed]
- van Lümig, P.P.; Driessen, R.J.; Berends, M.A.; Boezeman, J.B.; van de Kerkhof, P.C.; de Jong, E.M. Safety of treatment with biologics for psoriasis in daily practice: 5-year data. J. Eur. Acad. Dermatol. Venereol. 2012, 26, 283–291. [Google Scholar] [CrossRef] [PubMed]
- Alvarez, M.; Otano, I.; Minute, L.; Ochoa, M.C.; Perez-Ruiz, E.; Melero, I.; Berraondo, P. Impact of prophylactic TNF blockade in the dual PD-1 and CTLA-4 immunotherapy efficacy and toxicity. Cell Stress 2019, 3, 236–239. [Google Scholar] [CrossRef] [PubMed]
- Martora, F.; Martora, L.; Fabbrocini, G.; Marasca, C. A Case of Pemphigus Vulgaris and Hidradenitis Suppurativa: May Systemic Steroids Be Considered in the Standard Management of Hidradenitis Suppurativa? Skin. Appendage Disord. 2022, 8, 265–268. [Google Scholar] [CrossRef] [PubMed]
- Benoot, T.; Piccioni, E.; De Ridder, K.; Goyvaerts, C. TNFα and Immune Checkpoint Inhibition: Friend or Foe for Lung Cancer? Int. J. Mol. Sci. 2021, 22, 8691. [Google Scholar] [CrossRef] [PubMed]
- Geller, S.; Xu, H.; Lebwohl, M.; Nardone, B.; Lacouture, M.E.; Kheterpal, M. Malignancy Risk and Recurrence with Psoriasis and its Treatments: A Concise Update. Am. J. Clin. Dermatol. 2018, 19, 363–375. [Google Scholar] [CrossRef] [PubMed]
- Kaushik, S.B.; Lebwohl, M.G. Psoriasis: Which therapy for which patient: Psoriasis comorbidities and preferred systemic agents. J. Am. Acad. Dermatol. 2019, 80, 27–40. [Google Scholar] [CrossRef] [PubMed]
- Ngiow, S.F.; Teng, M.W.L.; Smyth, M.J. A balance of interleukin-12 and -23 in cancer. Trends Immunol. 2013, 34, 548–555. [Google Scholar] [CrossRef] [PubMed]
- He, D.; Li, H.; Yusuf, N.; Elmets, C.A.; Athar, M.; Katiyar, S.K.; Xu, H. IL-17 mediated inflammation promotes tumor growth and progression in the skin. PLoS ONE 2012, 7, e32126. [Google Scholar] [CrossRef]
- Lamb, C.A.; Kennedy, N.A.; Raine, T.; Hendy, P.A.; Smith, P.J.; Limdi, J.K.; Hayee, B.; Lomer, M.C.E.; Parkes, G.C.; Selinger, C.; et al. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019, 68, s1–s106. [Google Scholar]
- Megna, M.; Camela, E.; Battista, T.; Genco, L.; Martora, F.; Noto, M.; Picone, V.; Ruggiero, A.; Monfrecola, G.; Fabbrocini, G.; et al. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: Focus on pediatric patients. Expert. Opin. Drug Saf. 2023, 22, 25–41. [Google Scholar] [CrossRef]
- Megna, M.; Camela, E.; Battista, T.; Genco, L.; Martora, F.; Noto, M.; Picone, V.; Ruggiero, A.; Monfrecola, G.; Fabbrocini, G.; et al. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part II: Focus on elderly patients. Expert. Opin. Drug Saf. 2023, 22, 43–58. [Google Scholar] [CrossRef] [PubMed]
- Butrón-Bris, B.; Daudén, E.; Rodríguez-Jiménez, P. Psoriasis Therapy and Skin Cancer: A review. Life 2021, 11, 1109. [Google Scholar] [CrossRef] [PubMed]
- Yan, M.K.; Wang, C.; Wolfe, R.; Mar, V.J.; Wluka, A.E. Association Between Low-Dose Methotrexate Exposure and Melanoma: A Systematic Review and Meta-analysis. JAMA Dermatol. 2022, 158, 1157–1166. [Google Scholar] [CrossRef] [PubMed]
- Cockburn, I.T.; Krupp, P. The risk of neoplasm in patients treated with cyclosporine A. J. Autoimmun. 1989, 2, 723–773. [Google Scholar] [CrossRef]
- Paul, C.F.; Ho, V.C.; McGeown, C.; Christophers, E.; Schmidtmann, B.; Guillaume, J.C.; Lamarque, V.; Dubertret, L. Risk of malignancies in psoriasis patients treated with cyclosporine: A 5 y cohort study. J. Investig. Dermatol. 2003, 120, 211–216. [Google Scholar] [CrossRef]
- Berth-Jones, J. The use of ciclosporin in psoriasis. J. Dermatol. Treat. 2005, 16, 258–277. [Google Scholar] [CrossRef]
- Naldi, L. Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: Facts and controversies. Clin. Dermatol. 2010, 28, 88–92. [Google Scholar] [CrossRef]
- Kirby, B.; Owen, C.M.; Blewitt, R.W.; Yates, V.M. Cutaneous T-cell lymphoma developing in a patient on cyclosporin therapy. J. Am. Acad. Dermatol. 2002, 47 (Suppl. S2), S165–S167. [Google Scholar] [CrossRef]
- Corazza, M.; Zampino, M.R.; Montanari, A.; Altieri, E.; Virgili, A. Primary cutaneous CD30+ T-cell lymphoma in a patient with psoriasis treated with cyclosporine. Dermatology 2003, 206, 330–333. [Google Scholar] [CrossRef]
- Gambardella, A.; Licata, G.; De Rosa, A.; Calabrese, G.; Alfano, R.; Argenziano, G. Is Apremilast a Safe Option in Patients with History of Melanoma? A Case Series and a Review of the Literature. J. Clin. Aesthetic Dermatol. 2022, 15, 23–25. [Google Scholar]
- Nikolaou, V.; Sibaud, V.; Fattore, D.; Sollena, P.; Ortiz-Brugués, A.; Giacchero, D.; Romano, M.C.; Riganti, J.; Lallas, K.; Peris, K.; et al. Immune checkpoint-mediated psoriasis: A multicenter European study of 115 patients from the European Network for Cutaneous Adverse Event to Oncologic Drugs (ENCADO) group. J. Am. Acad. Dermatol. 2021, 84, 1310–1320. [Google Scholar] [CrossRef]
- Lemaitre, M.; Kirchgesner, J.; Rudnichi, A.; Carrat, F.; Zureik, M.; Carbonnel, F.; Dray-Spira, R. Association Between Use of Thiopurines or Tumor Necrosis Factor Antagonists Alone or in Combination and Risk of Lymphoma in Patients With Inflammatory Bowel Disease. JAMA 2017, 318, 1679–1686. [Google Scholar] [CrossRef] [PubMed]
- Mariette, X.; Tubach, F.; Bagheri, H.; Bardet, M.; Berthelot, J.M.; Gaudin, P.; Heresbach, D.; Martin, A.; Schaeverbeke, T.; Salmon, D.; et al. Lymphoma in patients treated with anti-TNF: Results of the 3-year prospective French RATIO registry. Ann. Rheum. Dis. 2010, 69, 400–408. [Google Scholar] [CrossRef] [PubMed]
- Patel, R.V.; Clark, L.N.; Lebwohl, M.; Weinberg, J.M. Treatments for psoriasis and the risk of malignancy. J. Am. Acad. Dermatol. 2009, 60, 1001–1017. [Google Scholar] [CrossRef]
- Askling, J.; Fored, C.M.; Baecklund, E.; Brandt, L.; Backlin, C.; Ekbom, A.; Sundström, C.; Bertilsson, L.; Cöster, L.; Geborek, P.; et al. Haematopoietic malignancies in rheumatoid arthritis: Lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann. Rheum. Dis. 2005, 64, 1414–1420. [Google Scholar] [CrossRef]
- Papp, K.A.; Strober, B.; Augustin, M.; Calabro, S.; Londhe, A.; Chevrier, M.; PSOLAR Investigators and Steering Committee. PSOLAR: Design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. J. Drugs Dermatol. 2010, 11, 1210–1217. [Google Scholar]
- Gubernatorova, E.O.; Polinova, A.I.; Petropavlovskiy, M.M.; Namakanova, O.A.; Medvedovskaya, A.D.; Zvartsev, R.V.; Telegin, G.B.; Drutskaya, M.S.; Nedospasov, S.A. Dual Role of TNF and LTα in Carcinogenesis as Implicated by Studies in Mice. Cancers 2021, 13, 1775. [Google Scholar] [CrossRef] [PubMed]
- Martora, F.; Megna, M.; Battista, T.; Potestio, L.; Annunziata, M.C.; Marasca, C.; Villani, A.; Fabbrocini, G. Adalimumab, Ustekinumab, and Secukinumab in the Management of Hidradenitis Suppurativa: A Review of the Real-Life Experience. Clin. Cosmet. Investig. Dermatol. 2023, 16, 135–148. [Google Scholar] [CrossRef]
- Battista, T.; Scalvenzi, M.; Martora, F.; Potestio, L.; Megna, M. Nail Psoriasis: An Updated Review of Currently Available Systemic Treatments. Clin. Cosmet. Investig. Dermatol. 2023, 16, 1899–1932. [Google Scholar] [CrossRef]
- Blauvelt, A.; Papp, K.A.; Griffiths, C.E.; Randazzo, B.; Wasfi, Y.; Shen, Y.K.; Li, S.; Kimball, A.B. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J. Am. Acad. Dermatol. 2017, 76, 405–417. [Google Scholar] [PubMed]
- Odorici, G.; Lasagni, C.; Bigi, L.; Pellacani, G.; Conti, A. A real-life experience of psoriatic patients with history of cancer treated with biological drugs. J. Eur. Acad. Dermatol. Venereol. 2019, 33, e453–e455. [Google Scholar] [CrossRef] [PubMed]
- Bellinato, F.; Gisondi, P.; Maurelli, M.; Girolomoni, G. IL-17A inhibitors in patients with chronic plaque psoriasis and history of malignancy: A case series with systematic literature review. Dermatol. Ther. 2021, 34, e14889. [Google Scholar] [CrossRef] [PubMed]
- Mastorino, L.; Dapavo, P.; Avallone, G.; Merli, M.; Cariti, C.; Rubatto, M.; Pala, V.; Quaglino, P.; Ribero, S. Biologic treatment for psoriasis in cancer patients: Should they still be considered forbidden? J. Dermatol. Treat. 2022, 33, 2495–2502. [Google Scholar] [CrossRef] [PubMed]
- Valenti, M.; Pavia, G.; Gargiulo, L.; Facheris, P.; Sanna, F.; Borroni, R.G.; Costanzo, A.; Narcisi, A. Biologic therapies for plaque type psoriasis in patients with previous malignant cancer: Long-term safety in a single-center real-life population. J. Dermatol. Treat. 2022, 33, 1638–1642. [Google Scholar] [CrossRef] [PubMed]
- Rusiñol, L.; Camiña-Conforto, G.; Puig, L. Biologic treatment of psoriasis in oncologic patients. Expert. Opin. Biol. Ther. 2022, 22, 1567–1578. [Google Scholar] [CrossRef] [PubMed]
- Finnegan, P.; Ahmad, K.; Sadlier, M.; Lynch, M. A retrospective review of the management of patients following a malignancy diagnosis on biologic therapies for the treatment of dermatological disorders. JAAD Case Rep. 2023, 39, 81–87. [Google Scholar] [CrossRef]
- Pellegrini, C.; Esposito, M.; Rossi, E.; Gisondi, P.; Piaserico, S.; Dapavo, P.; Conti, A.; Gambardella, A.; Burlando, M.; Narcisi, A.; et al. Secukinumab in Patients with Psoriasis and a Personal History of Malignancy: A Multicenter Real-Life Observational Study. Dermatol. Ther. 2022, 12, 2613–2626. [Google Scholar] [CrossRef] [PubMed]
- Magnano, M.; Balestri, R.; Gisondi, P.; Bardazzi, F.; Di Lernia, V.; Ioris, T.; Girardelli, C.R.; Rech, G. Biologics in psoriatic patients with malignancies: Where are we now? An Italian multicentric study. J. Eur. Acad. Dermatol. Venereol. 2024, 38, e331–e334. [Google Scholar] [CrossRef]
- Balato, A.; Lembo, S.; Cirillo, T.; Megna, M.; Raimondo, A.; Di Costanzo, L. Anti-Tumor Necrosis Factor-α Therapy in the Management of Psoriasis and B-Chronic Lymphocytic Leukemia. Case Rep. Dermatol. 2011, 3, 60–63. [Google Scholar] [CrossRef]
- Patel, S.; Patel, T.; Kerdel, F.A. The risk of malignancy or progression of existing malignancy in patients with psoriasis treated with biologics: Case report and review of the literature. Int. J. Dermatol. 2016, 55, 487–493. [Google Scholar] [CrossRef] [PubMed]
- Lasagni, C.; Bigi, L.; Conti, A.; Pellacani, G. Successful therapy of plaque-type psoriasis with secukinumab in patients with multiple comorbidities treated with previous biologic therapies. J. Dermatol. Treat. 2018, 29 (Suppl. S2), 5–8. [Google Scholar] [CrossRef] [PubMed]
- Gkalpakiotis, S.; Arenberger, P.; Fridman, M.; Arenbergerova, M. Long-term therapy with ustekinumab for psoriasis in a patient with a history of malignant melanoma. Dermatol. Ther. 2017, 30, e12522. [Google Scholar] [CrossRef]
- Ghazanfar, M.N.; Karlsmark, T.; Danielsen, P.L.; Thomsen, S.F. Sequential treatment with secukinumab and ustekinumab in a patient with severe psoriasis and recent history of cerebral malignant melanoma metastasis. Clin. Case Rep. 2019, 7, 1350–1351. [Google Scholar] [CrossRef] [PubMed]
- Kamiya, K.; Yamauchi, H.; Ohtsuki, M. Treatment of psoriasis vulgaris with guselkumab in a patient with non-small cell lung cancer. Eur. J. Dermatol. 2020, 30, 609–611. [Google Scholar] [CrossRef] [PubMed]
- Wang, D.M.; Fernandez, A.P.; Calabrese, C.M.; Calabrese, L.H. Treatment of psoriasis with ustekinumab in a patient with HIV-related Kaposi sarcoma. Clin. Exp. Dermatol. 2019, 44, 113–115. [Google Scholar] [CrossRef] [PubMed]
- Gambardella, A. Secukinumab in the Treatment of Plaque Psoriasis in Patients with Malignancy. Case Rep. Dermatol. 2019, 11 (Suppl. S2), 11–16. [Google Scholar] [CrossRef] [PubMed]
- Jin, J.Q.; Ahlstrom, J.M.; Sweeney, N.W.; Liao, W. Clinicalcharacteristics of 18 patients with psoriasis and multiple myeloma identified through digital health crowdsourcing. Dermatol. Ther. 2020, 10, 815–827. [Google Scholar] [CrossRef] [PubMed]
- Peter, J.K.; Muller, S.; Navarini, A.; Maul, L.V. Malignant melanoma in a psoriasis patient after sequential treatment with biologics. Dermatol. Ther. 2022, 35, e15435. [Google Scholar] [CrossRef]
- Porcar Saura, S.; Martínez Casimiro, L.; García Vázquez, A.; Pons Benavent, M.; Guillén-Climent, S.; Montesinos Villaescusa, E. Successful outcome of psoriasis in a laryngeal cancer patient treated with ixekizumab, a possible beneficial treatment for both pathologies. Dermatol. Online J. 2021, 27, 1–3. [Google Scholar] [CrossRef]
- Yan, J.; Smyth, M.J.; Teng, M.W.L. Interleukin (IL)-12 and IL-23 and their conflicting roles in cancer. Cold Spring Harb. Perspect. Biol. 2018, 10, a028530. [Google Scholar] [CrossRef] [PubMed]
Patient Number | Age | Sex | Cancer Onset | Cancer | Year of Cancer Diagnosis | Stage | Treatment | FUP | PASI | Previous Non- Biologic Systemic Treatment | Previous Biologic Treatment | Therapy Discontinuation after Tumor Diagnosis (Months) | Date of First Biologic Therapy after Cancer | Ongoing Biologic Therapy and Start Date | Months from Cancer Diagnosis and Biologic Therapy | FUP under Biologic after Cancer Diagnosis (Months) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | 62 | F | 45 | Endometrial cancer | 2006 | I | Surgery + RT | Regular | 25 | Methotrexate | None | None | 2018 | Ixekizumab (2018) | 144 | 60 |
2 | 42 | F | 40 | Breast cancer | 2021 | I | Surgery + RT + OT | Regular | 11.3 | None | None | None | 2022 | Secukinumab (2022) | 6 | 20 |
3 | 65 | M | 59 | Esophageal cancer | 2016 | IIA | Surgery + CT | Cancer progression | 14.5 | Methotrexate, Cyclosporine | Infliximab, Adalimumab, Ustekinumab | 18 | 2018 | Ustekinumab (2018) | 18 | 84 |
4 | 48 | F | 45 | Breast cancer | 2020 | I | Surgery | Regular | 30.2 | Methotrexate, Cyclosporine, Phototherapy | Adalimumab, Etanercept, Ustekinumab, Certolizumab | 18 | 2022 | Certolizumab (2022) | 18 | 20 |
5 | 30 | F | 28 | Thyroid cancer | 2021 | I | Surgery | Regular | 18.3 | Apremilast | None | None | 2022 | Tildrakizumab (2022) | 12 | 24 |
6 | 67 | F | 66 | Chronic lymphatic leukemia | 2022 | II | FUP | Regular | 15.6 | None | None | None | 2022 | Risankizumab (2022) | 6 | 12 |
7 | 55 | F | 48 | Chronic lymphatic leukemia | 2018 | I | FUP | Regular | 20.4 | Methotrexate | None | None | 2018 | Ustekinumab (2018) | 3 | 60 |
8 | 65 | M | 63 | Pulmonary cancer | 2021 | IV | Surgery + RT + CT | Regular | 12.5 | None | Guselkumab | 12 | 2022 | Secukinumab (2022) | 12 | 18 |
9 | 52 | F | 45 | Breast cancer | 2016 | IIIA | Surgery + RT + CT | Regular | 8.2 (palmo-plantar) | Cyclosporine | None | None | 2021 | Ixekizumab (2021) | 60 | 30 |
10 | 68 | M | 63 | Prostate cancer | 2018 | II | Surgery + RT | Regular | 24.6 | None | None | None | 2023 | Risankizumab (2023) | 60 | 6 |
11 | 70 | F | 60 | Breast cancer | 2013 | NA | Surgery + RT + CT | Regular | 9.3 (palmo-plantar and genitals) | Methotrexate, Cyclosporine | None | None | 2019 | Secukinumab (2019) | 72 | 48 |
12 | 73 | F | 65 | Breast cancer | 2015 | IIA | Surgery + RT + OT | Regular | 19.5 | Methotrexate | None | None | 2021 | Guselkumab (2021) | 72 | 24 |
13 | 53 | M | 50 | Thyroid cancer | 2020 | NA | Surgery + RT | Regular | 35.7 | Acitretin | None | None | 2022 | Secukinumab (2022) | 24 | 12 |
14 | 66 | M | 60 | Prostate cancer | 2017 | II | Surgery + RT | Regular | 23.8 | None | Adalimumab | 24 | 2022 | Ixekizumab (2022) | 60 | 24 |
15 | 75 | F | 64 | Breast cancer | 2014 | IV | Surgery + RT + CT | Regular | 40.1 | Methotrexate | None | None | 2019 | Guselkumab (2019) | 60 | 48 |
16 | 36 | F | 29 | Thyroid cancer | 2016 | II | Surgery + RT | Regular | 17.5 | None | None | None | 2022 | Secukinumab (2022) | 72 | 24 |
17 | 63 | M | 58 | Colo-rectal cancer | 2018 | NA | Surgery | Regular | 22.3 | Acitretin, methotrexate | None | None | 2023 | Guselkumab (2023) | 6 | 12 |
18 | 61 | M | 52 | Prostate cancer | 2014 | I | Surgery | Regular | 18.7 | Methotrexate, phototherapy | None | None | 2019 | Guselkumab (2019) | 84 | 48 |
19 | 52 | F | 47 | Breast cancer | 2017 | IIIA | Surgery + RT + CT | Regular | 19 | None | None | None | 2023 | Secukinumab (2023) | 72 | 1 |
20 | 70 | M | 69 | Pulmonary cancer | 2023 | III | CT + RT | Regular | 50 | None | Guselkumab | 12 | 2024 | Guselkumab (2024) | 12 | 1 |
Study | Biologic Drug (s) | Number of Patients Diagnosed with Cancer | Cancer Diagnosed | Average Time (Months) from Diagnosis to Biologics |
---|---|---|---|---|
Blauvelt et al. [62] | Guselkumab | 2 | Breast cancer Lung cancer | NA |
Van Lümig et al. [33] | Alefacept Etanercept Adalimumab | 4 | Breast cancer | 120 |
Odorici et al. [63] | Infliximab Etanercept Adalimumab Ustekinumab Secukinumab Efalizumab | 14 | Melanoma (2) Prostate carcinoma (4) Bladder adenocarcinoma (2) Lung adenocarcinoma (3) Rectal adenocarcinoma (2) Renal carcinoma (1) Breast adenocarcinoma (1) Non-melanoma skin cancers (1), myeloma (1) | 40.1 |
Bellinato et al. [64] | Ixekizumab Secukinumab | 12 | Melanoma (1) Lung cancer (2) Prostate acinar adenocarcinoma (3) Breast ductal carcinoma (1) Bladder cancer (1) Colon adenocarcinoma (2) Uterus adenocarcinoma (1) Thyroid medullary carcinoma (1) | 16.8 |
Mastorino et al. [65] | Guselkumab Brodalumab Secukinumab Ixekizumab Adalimumab Risankizumab | 37 | Leiomyosarcoma (1) Renal cancer (3) Ovarian cancer (1) Thyroid cancer (1) Larynx cancer (1) Non-melanoma skin cancer | 112.2 |
Valenti et al. [66] | Ixekizumab Secukinumab Ustekinumab Etanercept Risankizumab Guselkumab | 16 | Breast cancer (4) Non-Hodgkin Lymphoma (3) Renal cancer (2) Thyroid cancer (1) Both pheochromocytoma and thyroid cancer (1) Lung cancer (1) Brain cancer (1) Intestinal cancer (1) Uterine cancer (1) | 52 |
Rusiñol et al. [67] | Etanercept Adalimumab Ixekizumab Secukinumab Brodalumab Ustekinumab Risankizumab Guselkumab Tildrakizumab | 31 | Prostate cancer (4) Renal carcinoma (2) Bladder cancer (2) Breast cancer (6) Follicular lymphoma (2) Chronic lymphocytic leukemia (2) Diffuse large B cell lymphoma (1) Monoclonal gammopathy of undetermined significance (1) Colorectal carcinoma (1) Thyroid carcinoma (1) Melanoma (1) Gastric carcinoma (1) Head and neck cancer (1) Leiomyosarcoma (1) Chondrosarcoma (1) | NA |
Finnegan et al. [68] | Adalimumab Etanercept Ustekinumab | 11 | Breast cancer (1) Bladder cancer (1) Ovarian cancer (2) Lymphoma (3) Gastric cancer (1) Esophageal cancer (1) Melanoma (1) Testicular cancer | 24 |
Pellegrini et al. [69] | Secukinumab | 43 | Melanoma (8) Breast cancer (7) Bladder cancer (5) Colon cancer (7) Renal cancer (3) Lung cancer (5) Uterine cancer (1) Testicular cancer (1) Hodgkin lymphoma (1) | 42 |
Magnano et al. [70] | 73 | Breast cancer Lymphomas Prostate cancer Kidney cancer Lung cancer Colorectal cancer Bladder cancer Uterus cancer Thyroid cancer Larynx cancer Melanoma Testicular cancers Non-melanoma skin cancer Hepatocarcinoma | 28.06 (Group 2: Patients with recent diagnosis of malignancy) 109.2 (Group 3: Patients with malignancies who started a biologic after 5 years) | |
Balato et al. [71] | Etanercept Infliximab | 1 | Chronic lymphocytic leukemia | 0 |
Patel et al. [72] | Etanercept Ustekinumab | 1 | Colon cancer | 13 |
Lasagni et al. [73] | Secukinumab Ustekinumab | 1 | Breast cancer | 22 |
Gkalpakiotos et al. [74] | Etanercept Ustekinumab | 1 | Melanoma | 84 |
Ghazanfar et al. [75] | Secukinumab Ustekinumab | 1 | Melanoma | 7 |
Kamiya et al. [76] | Guselkumab | 1 | Lung cancer | 2 |
Wang et al. [77] | Ustekinumab | 1 | Kaposi sarcoma | 18 |
Gambardella et al. [78] | Secukinumab | 1 | Bladder cancer | 12 |
Jin et al. [79] | Ixekizumab | 1 | Multiple myeloma | 0 |
Peter et al. [80] | Secukinumab | 1 | Melanoma | NA |
Porcar Saura et al. [81] | Etanercept Adalimumab Ixekizumab | 1 | Laryngeal squamous cell carcinoma | 5 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Battista, T.; Gallo, L.; Martora, F.; Fattore, D.; Potestio, L.; Cacciapuoti, S.; Scalvenzi, M.; Megna, M. Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study. J. Clin. Med. 2024, 13, 1940. https://doi.org/10.3390/jcm13071940
Battista T, Gallo L, Martora F, Fattore D, Potestio L, Cacciapuoti S, Scalvenzi M, Megna M. Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study. Journal of Clinical Medicine. 2024; 13(7):1940. https://doi.org/10.3390/jcm13071940
Chicago/Turabian StyleBattista, Teresa, Lucia Gallo, Fabrizio Martora, Davide Fattore, Luca Potestio, Sara Cacciapuoti, Massimiliano Scalvenzi, and Matteo Megna. 2024. "Biological Therapy for Psoriasis in Cancer Patients: An 8-Year Retrospective Real-Life Study" Journal of Clinical Medicine 13, no. 7: 1940. https://doi.org/10.3390/jcm13071940